bioRxiv 2025
Then comes a recommendation We recommend that treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) be initiated in patients with diabetes, hypertension, and albuminuria, and that these medications be titrated to the highest approved dose that is tolerated (1B)
Its crucial to follow safety guidelines: never use more than one dose in a 24-hour period and limit your use to eight doses per month
pseudomallei , whereby an extracellular histidine kinase domain binds GSH to initiate expression of the type VI secretion system to initiate virulence 15
GLP-1 products have the potential to narrow health disparities by addressing a key driver of chronic disease
Deeply understand physician and payer dynamics, and build strategy accordingly: Deeply understand physician and payer dynamics, and build strategy accordingly: Understanding the differences between primary care provider versus endocrinologist perceptions and prescribing behaviors (e.g., class preferences, route of administration preferences, etc.) is foundational to developing strategies that account for stakeholder-specific nuances
